Follow the 휴마시스 stock price and the full insider trade history of the company, a listed issuer based in South Korea. Shares are listed on the KR market, under the authority of DART (FSS). Operating in the Health Care sector, 휴마시스 has recorded 58 insider filings. Market capitalisation: €69.9bn. The latest transaction was filed on 10 July 2026 (Other). Among the most active insiders: 아티스트. All data is openly available.
47
Insider Decl.
n/a
Thresholds
€3m
14 ops.
Buy Volume
n/a
7 ops.
Sell Volume
25Σ signal
Buys €3mn/a Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 23,645 of 29,064 companies
29.7
score / 100
Value
49
Quality
11
FCF yld14%
Earn yld-22%
EV/EBITDA·
ROE-6.5%
Gross mgn7.4%
Net mgn-52%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
Humasis is a company specializing in the health and pharmaceutical sector, listed on the XKRX market. It focuses on the development of medical diagnostics and innovative health solutions.